14,667,491 Shares in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Acquired by Softbank Group CORP.

Softbank Group CORP. acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,667,491 shares of the company's stock, valued at approximately $99,152,000. Recursion Pharmaceuticals accounts for approximately 0.4% of Softbank Group CORP.'s investment portfolio, making the stock its 10th biggest position. Softbank Group CORP. owned 3.75% of Recursion Pharmaceuticals as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. grew its stake in Recursion Pharmaceuticals by 40.1% in the 4th quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares in the last quarter. Novo Holdings A S purchased a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $68,375,000. Geode Capital Management LLC grew its stake in Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company's stock worth $41,160,000 after purchasing an additional 655,238 shares in the last quarter. Norges Bank purchased a new position in Recursion Pharmaceuticals during the 4th quarter worth $23,429,000. Finally, Laurion Capital Management LP purchased a new position in shares of Recursion Pharmaceuticals during the fourth quarter valued at $16,611,000. Hedge funds and other institutional investors own 89.06% of the company's stock.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several recent research reports. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners lowered their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Needham & Company LLC reduced their target price on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Morgan Stanley cut their price target on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $7.60.

Recursion Pharmaceuticals Price Performance

RXRX traded down $0.40 during trading on Wednesday, reaching $4.16. The company's stock had a trading volume of 12,415,121 shares, compared to its average volume of 13,225,594. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The company has a market cap of $1.69 billion, a price-to-earnings ratio of -2.73 and a beta of 0.99. The firm has a fifty day simple moving average of $5.28 and a two-hundred day simple moving average of $6.56. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. During the same period in the prior year, the company posted ($0.39) EPS. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.